Morten Orebo Holmström (Morten Holmström, Morten O Holmström)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Oncoimmunology

Cellular & molecular immunology

Journal for immunotherapy of cancer

Cancer immunology, immunotherapy : CII

Zealand University Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zealand University Hospital Oct 01 2014 - Mar 31 2019

Denmark

Ph. D. student :: Department of Hematology

Publications

Morten Orebo Holmström, Josephine Hallundbæk Ruders, Caroline Hasselbalch Riley, Morten Kranker Larsen, Jacob Handlos Grauslund, Lasse Kjaer, Vibe Skov, Christina Ellervik, Belinda B Guo, Matthew Linden, Hans Carl Carl Hasselbalch, Mads Hald Andersen
The CALR mutations enhance the expression of the immunosuppressive proteins GARP and LAP on peripheral blood lymphocytes through increased binding of activated platelets. British journal of haematology (2024)
Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle, Jane P Hasselby, Gro L Willemoe, Özcan Met, Inge Marie Svane, Julia Johansen, Dorte L Nielsen, Inna M Chen, Mads Hald Andersen
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. Journal for immunotherapy of cancer 11 (3) (2023)
Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle, Jane P Hasselby, Gro L Willemoe, Özcan Met, Inge Marie Svane, Julia Johansen, Dorte L Nielsen, Inna M Chen, Mads Hald Andersen
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. Journal for immunotherapy of cancer 11 (3) (2023)
Simone Kloch Bendtsen, Maria Perez-Penco, Mie Linder Hübbe, Evelina Martinenaite, Morten Orebo Holmström, Stine Emilie Weis-Banke, Nicolai Grønne Jørgensen, Mia Aaboe Jørgensen, Shamaila Munir Ahmad, Kasper Mølgaard Jensen, Christina Friese, Mia Thorup Lundsager, Astrid Zedlitz Johansen, Marco Carretta, Niels Odum, Özcan Met, Inge Marie Svane, Daniel Hargbøl Madsen, Mads Hald Andersen
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment. Oncoimmunology 11 (1) (2022)
Mathieu Gigoux, Morten Orebo Holmström, Roberta Zappasodi, Joseph J Park, Stephane Pourpe, Cansu Cimen Bozkus, Levi Mark Mangarin, David Redmond, Svena Verma, Sara Schad, Mariam M George, Divya Venkatesh, Arnab Ghosh, David Hoyos, Zaki Molvi, Baransel Kamaz, Anna E Marneth, William Duke, Matthew Joseph Leventhal, Max Jan, Vincent T Ho, Gabriela S Hobbs, Trine Alma Knudsen, Vibe Skov, Lasse Kjær, Thomas Stauffer Larsen, Dennis Lund Hansen, R Coleman Lindsley, Hans Carl Carl Hasselbalch, Jacob H Grauslund, Thomas L Lisle, Özcan Met, Patrick Wilkinson, Benjamin Greenbaum, Manuel A Sepulveda, Timothy A Chan, Raajit Rampal, Mads Hald Andersen, Omar Abdel-Wahab, Nina Bhardwaj, Jedd D Wolchok, Ann Mullally, Taha Merghoub
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine 14 (649) (2022)
Morten Orebo Holmström, Rasmus Erik Johansson Mortensen, Angelos Michail Pavlidis, Evelina Martinenaite, Stine Emilie Weis-Banke, Mia Aaboe-Jørgensen, Simone Kloch Bendtsen, Özcan Met, Ayako Wakatsuki Pedersen, Marco Donia, Inge Marie Svane, Mads Hald Andersen
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner. Cellular & molecular immunology 18 (2) (2021)
Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Mads Hald Andersen
Characterization of TGFβ-specific CD4+T cells through the modulation of TGFβ expression in malignant myeloid cells. Cellular & molecular immunology 18 (11) (2021)
Stine Emilie Weis-Banke, Mie Linder Hübbe, Morten Orebo Holmström, Mia Aaboe Jørgensen, Simone Kloch Bendtsen, Evelina Martinenaite, Marco Carretta, Inge Marie Svane, Niels Ødum, Ayako Wakatsuki Pedersen, Özcan Met, Daniel Hargbøl Madsen, Mads Hald Andersen
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines. Oncoimmunology 9 (1) (2020)
Morten Orebo Holmström, Sabrina Cordua, Vibe Skov, Lasse Kjær, Niels Pallisgaard, Christina Ellervik, Hans Carl Hasselbalch, Mads Hald Andersen
Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer immunology, immunotherapy : CII 69 (2) (2020)
Morten Orebo Holmström, Guy W Novotny, Jesper Petersen, Mia Aaboe-Jørgensen, Hans Carl Hasselbalch, Mads Hald Andersen, Signe Ledou Nielsen, Daniel El Fassi, Claudia Schöllkopf
Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy. Leukemia & lymphoma 60 (13) (2019)
Morten Orebo Holmström, Shamaila M Ahmad, Uffe Klausen, Simone K Bendtsen, Evelina Martinenaite, Caroline H Riley, Inge M Svane, Lasse Kjær, Vibe Skov, Christina Ellervik, Niels Pallisgaard, Hans C Hasselbalch, Mads H Andersen
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood cancer journal 9 (2) (2019)
Morten Orebo Holmström, Hans Carl Carl Hasselbalch, Mads Hald Andersen
Neo-antigen specific memory T-cell responses in healthy individuals. Oncoimmunology 8 (7) (2019)
Morten Orebo Holmström, Hans Carl Hasselbalch
Cancer immune therapy for myeloid malignancies: present and future. Seminars in immunopathology 41 (1) (2018)
Julia Czech, Sabrina Cordua, Barbora Weinbergerova, Julian Baumeister, Assja Crepcia, Lijuan Han, Tiago Maié, Ivan G Costa, Bernd Denecke, Angela Maurer, Claudia Schubert, Kristina Feldberg, Deniz Gezer, Tim H Brümmendorf, Gerhard Müller-Newen, Jiri Mayer, Zdenek Racil, Blanka Kubesova, Trine Knudsen, Anders L Sørensen, Morten Orebo Holmström, Lasse Kjær, Vibe Skov, Thomas Stauffer Larsen, Hans C Hasselbalch, Nicolas Chatain, Steffen Koschmieder
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia 33 (4) (2018)
Mia Aaboe Jørgensen, Morten Orebo Holmström, Evelina Martinenaite, Caroline Hasselbalch Riley, Hans Carl Carl Hasselbalch, Mads Hald Andersen
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. Oncoimmunology 7 (9) (2018)

Morten Orebo Holmström.css-eqlu8i{font-size:small;padding-left:4px;} (Morten Holmström, Morten O Holmström)

Publication Activity (10 Years)

Top Topics

Top Venues

Morten Orebo Holmström (Morten Holmström, Morten O Holmström)